Vertex Planning Phase 3 Trials in New Triple Combo Therapy for CF

Vertex Planning Phase 3 Trials in New Triple Combo Therapy for CF

301228

Vertex Planning Phase 3 Trials in New Triple Combo Therapy for CF

Vertex Pharmaceuticals is initiating two Phase 3 clinical trials into the safety and efficacy of a potentially new, next-generation triple combination therapy for cystic fibrosis (CF): VX-121 plus tezacaftor and VX-561 (deutivacaftor). Expected to begin later this year, the development program will compare this once-daily therapy with Vertex’s Trikafta, also a combination of three CF medicines — elexacaftor, tezacaftor, and ivacaftor — taken daily. The investigative treatment has shown a potential “to drive higher levels…

You must be logged in to read/download the full post.